It's a major expansion from a Feb. 16 advisory that limited such screening to areas with active Zika virus transmission.
In a statement released Friday, the FDA says all those areas are currently in compliance with blood screening but that expanded testing is now needed.
"As new scientific and epidemiological information regarding Zika virus has become available, it's clear that additional precautionary measures are necessary," the FDA's acting chief scientist, Luciana Borio, said in the statement.
The expansion of testing won't happen all at once. The FDA is advising blood establishments in 11 states to begin testing within the next four weeks. Those states include Alabama, Arizona, California, Georgia, Hawaii, Louisiana, Mississippi, New Mexico, New York, South Carolina and Texas.
These states are in proximity to areas where Zika is actively spreading via mosquitoes or where there are a significant number of cases related to other exposures, including sexual transmission.
Within 12 weeks, blood facilities in all states should be testing donations for Zika, the FDA says.